The sovereign mandate.
Why a domestic supply of essential medicine is national infrastructure, and how Adjuvant Bio is built to hold it.
Localize. Manufacture. Protect.
A supply chain that crosses three borders before it reaches a pharmacy is a supply chain that can be cut. Adjuvant Bio brings the whole chain home: molecule, drug substance, fill-finish and distribution, under one quality system.
The regional biotech anchor.
Beyond supply security, a domestic manufacturer seeds an ecosystem: skilled jobs, a research base, and a platform that partners can build on. That is the return the mandate is written to deliver.
The people accountable for the supply.
Two decades scaling sterile biologics manufacturing across three continents.
Led biosimilar characterization programs from candidate to commercial supply.
Built the fill-finish network and the cold-chain that keeps it moving.
Shepherded accelerated-pathway filings across major and emerging markets.
Core values.
Integrity
Data integrity is not a policy, it is the product. ALCOA+ by construction.
Innovation
Biosimilars are an analytics problem. We invest where the science is hardest.
Collaboration
Sovereign does not mean isolated. We build with the institutions that matter.
Excellence
One quality system, every batch, every market. No second tier.
Operational framework.
Scientific Advisory
An external board that governs the pipeline and the platform.
Risk & Audit
Independent oversight of quality, supply and financial risk.
Regulatory & QC
Filing strategy and release testing under one accountable owner.
Manufacturing Ops
The people who run the lines, the network and the cold chain.
Partner on the mandate.
Procurement, co-development, or technology transfer. Start a conversation with the supply team.